Michael G Benatar

Professor

  • 7944 Citations
1994 …2023
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Michael G Benatar is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Amyotrophic Lateral Sclerosis Medicine & Life Sciences
Myasthenia Gravis Medicine & Life Sciences
Mutation Medicine & Life Sciences
Biomarkers Medicine & Life Sciences
Polyneuropathies Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Prednisone Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2008 2023

Biomarkers
Asymptomatic Diseases
Therapeutics
Organized Financing
Antisense Oligonucleotides
National Institute of Neurological Disorders and Stroke
Clinical Trials
Hispanic Americans
Research Personnel
Research
Validation Studies
Biomarkers
Cerebrospinal Fluid
Intermediate Filaments
Therapeutic Uses
Gene-Environment Interaction
Amyotrophic Lateral Sclerosis
Environmental Exposure
Registries
Mendelian Randomization Analysis
Patient Advocacy
Research
Biomarkers
Exome
Rare Diseases

Research Output 1994 2019

2 Citations (Scopus)

An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis

Gertsman, I., Wuu, J., McAlonis-Downes, M., Ghassemian, M., Ling, K., Rigo, F., Bennett, F., Benatar, M. G., Miller, T. M. & Da Cruz, S., Jan 1 2019, In : JCI Insight. 4, 10, e122768.

Research output: Contribution to journalArticle

Open Access
Amyotrophic Lateral Sclerosis
Peptides
Cerebrospinal Fluid
Biomarkers
Mutation
Open Access
Myasthenia Gravis
Internet
Fatigue
Quality of Life
Research
2 Citations (Scopus)

Defining pre-symptomatic amyotrophic lateral sclerosis

Benatar, M. G., Turner, M. R. & Wuu, J., Jan 1 2019, In : Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.

Research output: Contribution to journalReview article

Amyotrophic Lateral Sclerosis
Asymptomatic Diseases
Neurodegenerative Diseases
Antisense Oligonucleotides
Genetic Therapy
2 Citations (Scopus)

Eculizumab improves fatigue in refractory generalized myasthenia gravis

The REGAIN Study Group, Jan 1 2019, In : Quality of Life Research.

Research output: Contribution to journalArticle

Open Access
Myasthenia Gravis
Fatigue
Activities of Daily Living
Placebos
eculizumab

Editorial: We may need large trials to find treatments for neurodegenerative diseases

Schoenfeld, D. A. & Benatar, M. G., Jan 1 2019, (Accepted/In press) In : Clinical Trials.

Research output: Contribution to journalArticle

Neurodegenerative Diseases
Sample Size
Parkinson Disease
Alzheimer Disease
Clinical Trials